Castle Biosciences, Inc.· CSTL
🇺🇸 US · SmallBroad USNASDAQ
- Price
- $31.18
- Day
- +2.60%
- Mkt Cap
- $952.53M
- 52W Range
- $17.72 – $44.28
- Volume
- 621.0K
- Beta
- 1.00
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Castle Biosciences (NASDAQ: CSTL - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Castle Biosciences
Read full article
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
Read full article
Castle Biosciences NASDAQ: CSTL reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous range of $345 million to $355 million.
Read full article
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to earnings of $0.15 per share a year ago.
Read full article
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.
Read full article